Stocks
Zynerba PharmaceuticalsZYNE
HealthcareBiotechnology
A clinical-stage pharmaceutical company developing synthetic cannabinoid therapies for rare and serious neurological disorders. Its lead candidate, Zygel, is a cannabidiol gel in late-stage trials for conditions such as Fragile X syndrome and developmental and epileptic encephalopathies. Investors track the stock for its pipeline catalysts and potential FDA approval decisions.
Congressional Interest in Zynerba Pharmaceuticals (ZYNE)
1 member of Congress has disclosed 1 trade in Zynerba Pharmaceuticals (ZYNE), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading ZYNE?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-03-09 | MICHAEL T. MCCAUL | buy | $1K-$15K |